Drugs / Collagen-Polyvinylpyrrolidone
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06585319 | Feb 2020 → Jun 2021 | COVID-19 | Materno-Perinatal Hospital of the State of Mexico | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07692009 | Jan 2024 → Jun 2026 | osteoarthritis, knee | Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04517162 Comparator | Aug 2020 → Feb 2021 | COVID-19, cytokine release syndrome, immune dysregulation, autoimmunity, and autoinflammation, pulmonary fibrosis | Janette Furuzawa Carballeda | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | collagen-polyvinyl pyrrolidone | “Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine” NCT07692009 ↗ |
| Known as | collagen-PVP | “Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine” NCT07692009 ↗1“Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms.” NCT06585319 ↗ |
| Action | Inhibit | “as a potential drug for the downregulation of the cytokine storm” NCT04517162 ↗ |
| Modality | Protein / enzyme biologic | “Polymerized-type I collagen (polymerized collagen) is a downmodulator of inflammation and cartilage regenerator biodrug.” PMID 22545014 ↗ Apr 2012 |
| Route | Intramuscular | “Participants will receive an intramuscular dose of either PTIC” NCT04517162 ↗ |